Daewoong Pharmaceutical(164,500 +4.11%)Announced on the 25th that it has received approval from the Ministry of Food and Drug Safety for Phase 3 clinical trials for preventing COVID-19 of Hoy Star Tablet (ingredient name camostat mesylate).
This clinical trial confirms the effects of Hoystar tablets in preventing infection in self-quarantine individuals exposed to the Corona 19 virus. A total of 1012 people are randomly assigned, placebo-controlled, and double-blinded at Samsung Medical Center and Asan Hospital, and administration is scheduled to start next month.
Hoystar tablet is a drug that inhibits the proliferation of viruses and improves inflammation by blocking the entry of viruses that have entered the human body into cells. It has been prescribed to patients for more than 10 years in Korea and has proven its safety, and it has the advantage of being convenient to take as a pill. In addition, considering the mechanism of blocking the entry of the virus by inhibiting the activity of the protease (TMPRSS2) required for the entry of the virus into the cell, it is expected to be able to respond regardless of the virus mutation, which is a recent issue.
Daewoong Pharmaceutical said, “Hoystar tablets are convenient to be taken orally and are expected to be the most effective in the initial process of the virus starting to replicate.” It is expected to provide treatment options for the company.”
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution